# Role of Omega-DEK in Childhood Apraxia of Speech

> **NCT07216001** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Claudia R. Morris** · enrollment: 34 (estimated)

## Conditions studied

- Childhood Apraxia of Speech
- Verbal Apraxia
- Autism

## Interventions

- **DRUG:** Omega-DEK
- **DRUG:** L-carnitine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07216001
- **Lead sponsor:** Claudia R. Morris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216001, "Role of Omega-DEK in Childhood Apraxia of Speech". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07216001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*